Table 1.
Summary of previous reports of allogeneic transplant outcomes in patients with recurrent/refractory lymphoma
| N of patients |
Age (Range) |
Resistant disease (N) | Donor Type | Conditioning Regimen |
NRM (years) |
Relapse (years) |
OS (Years) |
PFS (years) |
aGVHD | cGVHD | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Truelove et al.12 | 46 | 44.8 (18-59) | PR: (34); CR-1: (22) |
MSD: 69 MUD: 23% mMUD: 6.6% |
BEAM CAMPATH | 11%(5) | 53%(5) | 42%(5) | 36%(5) | 15% | 28% |
| Law et al.37 | 31 | 36 (20-60) | CR: (8); PR: (15); IF: (8) |
MSD | CBV | 31%(1) | 25%(1) | 47%(1) | 44%(1) | 29% | 39% |
| Rossi et al.38 | 18 | 42 (18-55) | CR: (10); Resistant: (5); Therapy related death: (3) |
MSD | CBV | 17%(3) | 27%(3) | 76%(2) | 56%(2 ) | 22% | 22% |
| Lazrus 39 | 79 | 46 (21-59) | 42% | MRD: 100% | CY+TBI (12Gy)/+ BU (82%) | 28%(3) | 33%(5) | 52%(3) | 22%(5) | 42% | 26% |
| Van Kampen et al.40 | 101 | 46 (18-66) | 26% | MRD: 71% MUD: 29% |
CY+TBI (12Gy)/± VP-16 + BU (82%) | 28%(3) | 30%(3) | 52%(3) | 42%(3) | 51% | 42% |
| Bacher et al.41 | 396 | 48 (18-69) | 32% | MRD: 33% MUD: 67% |
MAC: CY+TBI (12GY)/+ BU (77%) | 56%(5) | 26%(5) | 18%(5) | 18%(5) | 43% | 37% |
| Rezvani et al.42 | 32 | 52 (18-67) | 72% | MRD: 66% MUD: 34% |
Flu/TBI (2Gy) | 25%(3) | 41%(3) | 45%(3) | 35%(3) | 53% | 44% |
| Hamdani et al.8 | MAC: 307 | 46 (19-66) | 100% | MSD: 60% MUD: 30% mMUD: 10% |
Cy/TBI; BuCy | 53%(3) | 28%(3) | 19%(3) | 19%(3) | 29% | 33% |
| RIC: 226 | 53 (20-70) | 100% | MSD: 47% MUD: 31% MSD: 47% |
Flu/Mel; Flu/Bu ± TBI |
42%3) | 35%(3) | 28%(3) | 23%(3) | 31% | 38% | |
| Glass et al.43 | 84 | 48 (18-65) | Rituxan: 55% | MSD: 31% MUD: 33% mMUD: 36% |
Flu/Bu/CY+ Rituxan | 34%(1) | 29%(1) | 52%(4) | 45%(1) | 46% | 33% |
| No rituxan: 55% | MSD: 24% MUD: 48% mMUD: 26% |
Flu/Bu/CY | 37%(1) | 42% | 41% | ||||||
| Thomson et al.7 | 48 | 46 (23-64) | 17 | MRD: 62% MUD: 38% |
Flu/Mel + CAMPATH | 32%(4) | 33%(4) | 47%(4) | 48%(4) | 17% | 22% |
| Brammer et al.31 | 22 | 46 (20-62) | 9% | Haplo | Flu/Mel/TBI (2Gy) | 20%(1) | 27%(2) | 54%(2) | 54%(2) | 51% | 3% |
| Deithrich et al. | 59 | N/A | N/A | Haplo | Flu/Bu ± TBI or Flu/TBI | 25%(2) | 27%(2) | 56%(2) | 50%(2) | ||
| Kanate et al.32 | 185 | 55 (18-75) | 5.4 | Haplo | Flu/Cy/TBI (2gy) | 16%(2) | 34%(2) | 63%(2) | 50%(2) | 8% | 13% |